Anavex Life Sciences (AVXL) Stock Price, News & Analysis

Company Overview

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia. Anavex also holds ANAVEX3‐71, a muscarinic receptor agonist, in its pipeline for Rett syndrome and other developmental disorders. Through these programs, the company aims to demonstrate disease‐modifying effects by addressing underlying cellular dysfunction rather than solely managing symptoms.

Since its founding in 2012, Anavex has completed multiple Phase I and Phase II trials in North America and Europe, collaborating with academic research centers and contract research organizations to support its clinical development. The company has established manufacturing partnerships to ensure supply of clinical‐grade API and plans to expand its trial network into additional regions as programs advance. Christopher U. Missling serves as President and CEO, bringing more than two decades of experience in pharmaceutical research and development. Under his leadership, Anavex continues to explore strategic collaborations and funding opportunities to propel its pipeline toward regulatory milestones.

Key Stats

• Today's Range: $3.16 to $3.29
• 50-Day Range: $2.34 to $3.51
• 52-Week Range: $2.26 to $10.40
• Volume: 480,718 shs
• Average Volume: 880,815 shs
• Market Capitalization: $300.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.33
• Consensus Rating: Hold

Anavex Life Sciences Stock Analysis - MarketRank™

Anavex Life Sciences scored higher than 23% of companies evaluated by MarketBeat, and ranked 805th out of 915 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Anavex Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Anavex Life Sciences has a consensus price target of $21.33, representing about 558.4% upside from its current price of $3.24.

Amount of Analyst Coverage

Anavex Life Sciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Anavex Life Sciences are expected to decrease in the coming year, from ($0.33) to ($0.55) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Anavex Life Sciences is -8.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Anavex Life Sciences is -8.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Anavex Life Sciences has a P/B Ratio of 2.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.49% of the float of Anavex Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

Anavex Life Sciences has a short interest ratio ("days to cover") of 14.43, which indicates bearish sentiment.

Change versus previous month

Short interest in Anavex Life Sciences has recently increased by 2.03%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Anavex Life Sciences does not currently pay a dividend.

Dividend Growth

Anavex Life Sciences does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 4 news articles for Anavex Life Sciences this week, compared to 4 articles on an average week.

Search Interest

Only 6 people have searched for AVXL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

3 people have added Anavex Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Anavex Life Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.00% of the stock of Anavex Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

31.55% of the stock of Anavex Life Sciences is held by institutions.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 8/23/2026
• Next Earnings (Estimated): 8/24/2026
• Fiscal Year End: 9/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:AVXL
• CIK: 1314052
• Web: www.anavex.com
• Phone: (844) 689-3939
• Fax: N/A
• Employees: 40
• Year Founded: 2006

Price Target and Rating

• Average Price Target for Anavex Life Sciences: $21.33
• High Price Target: $24.00
• Low Price Target: $20.00
• Potential Upside/Downside: +558.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.39)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$46.38 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -32.73%
• Return on Assets: -30.15%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 20.87
• Quick Ratio: 20.87

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.10 per share
• Price / Book: 2.95

Miscellaneous

• Outstanding Shares: 92,700,000
• Free Float: 82,500,000
• Market Cap: $300.35 million
• Optionable: Optionable
• Beta: 1.15